clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT02394795 |
P6099 | clinical trial phase | phase III clinical trial | Q42824827 |
P17 | country | Japan | Q17 |
P582 | end time | 2020-03-01 | |
P4135 | maximum age | 79 | |
P2899 | minimum age | 20 | |
P1132 | number of participants | 823 | |
P4844 | research intervention | bevacizumab | Q413299 |
leucovorin calcium | Q27077063 | ||
fluorouracil | Q238512 | ||
calcium oxalate | Q412399 | ||
P1813 | short name | PARADIGM | |
P580 | start time | 2015-04-01 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | A Phase III, Randomized, Controlled Study of mFOLFOX6 + Bevacizumab Combination Therapy Versus mFOLFOX6 + Panitumumab Combination Therapy in Chemotherapy-naive Patients With KRAS/NRAS Wild-type, Incurable/Unresectable, Advanced/Recurrent Colorectal Cancer |
Search more.